— Know what they know.
/
Not Investment Advice

GEHC

NASDAQ · USD
GE HealthCare Technologies Inc.
Healthcare · Medical - Devices
CEO Peter J. Arduini Employees 54,000 R&D / revenue 6.1%
Last price
$69.57−1.11%last session
Market cap
$31.4B
P/E (TTM)
20.0x
From 52w high
−22.5%
From 52w low
+18.4%
1-year return
−5.2%
RSI 14 · vs SMA200
61.0 · −1.3%
IS score
26.1/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

GEHC   SPY   XLV (sector ETF) · weekly closes
8090100110120Jan 26Apr 26Jul 26Oct 26XLV 124SPY 116GEHC 95

Score DNA

Each bar is a 0-100 score within the scored universe
46
Profitability
23
Growth
57
Value
44
Momentum
30
Risk (safety)
61
Quality
48
Balance sheet
70
Earnings quality

Flags

Strengths
✓ Insider buying✓ Congress buying
Warnings
▲ Altman distress zone
Observations
Moat model: Weak, Cost AdvantagePiotroski 5 / 9Altman Z 1.7Beta 0.824 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
8
$6.42M bought
Form 144 notices (12m): 2, $715,038 proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
6
Last disclosed purchase 2026-09-11
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−37
142 new holders, 163 closed
1,230 filers hold 87.7% · 398 added, 471 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+198
1,125 funds adding shares
927 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
56.3%
20-day avg 62.0%, 50-day avg 60.5%
Latest 5.7 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$20.6B
Revenue growth YoY+4.8%
Gross margin40.0%
Operating income$2.8B
Operating margin13.4%
Net income$2.1B
Net margin10.1%
EPS (diluted)$4.55
Cash flow
Operating cash flow$2.0B
Capital expenditure$482.0M
Free cash flow$1.5B
FCF conversion (FCF / OCF)75.8%
Stock-based compensation$130.0M
FCF less SBC$1.4B
Buybacks$200.0M
Dividends$64.0M
Balance sheet & returns
Cash & short-term investments$4.5B
Total debt$10.0B
Net debt$5.5B
Shareholders' equity$10.6B
Goodwill & intangibles$14.6B
Debt / equity0.92
ROE (TTM)15.2%
ROIC (TTM)8.1%
Operating margin by fiscal year
15.7%FY202212.5%FY202313.3%FY202413.3%FY2025
Revenue $17.6B (FY2021) to $20.6B (FY2025), a 4.1% CAGR.

Valuation

P/E (TTM)20.0x
EV / EBITDA12.8x
Price / sales1.55x
Price / FCF35.1x
FCF yield2.85%
Buyback yield0.64%
SBC / revenue0.6%
Price / book2.87x
Forward P/E FY202614.1x
Forward P/E FY202712.8x
Forward P/E FY202811.5x
Forward multiples divide today's price by Street EPS estimates. Street mean target $85.25 across 4 analysts last quarter is theirs, not ours.

GEHC vs industry median

318 companies in Medical - Devices
Gross margin 42.9% 57.3% Operating margin 12.7% -22.8% Net margin 7.9% -23.0% ROIC 8.1% -5.0%
GEHC (TTM)Industry median Asset turnover 0.54 vs industry 0.55 · financial leverage 3.39

Earnings delivery

Next report 2026-10-28 · consensus EPS $1.21
83%
beat rate, 10 of 12 quarters
+8.6%
median EPS surprise
7
longest beat streak
+10+10-1+2+9+15+11+15+2+3-5+9
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-31 to 2026-07-29. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
GEHC GE HealthCare Technologies I $31.4B20.0x15.2%7.9%+4.8% −5.2%
DXCM DexCom, Inc. $32.5B33.2x38.5%19.0%+15.5% +29.7%
EW Edwards Lifesciences Corpora $49.9B49.8x9.5%13.9%+14.6% +19.2%
ZBH Zimmer Biomet Holdings, Inc. $18.1B23.0x6.4%9.1%+8.6% −5.0%
BSX Boston Scientific Corporatio $64.3B17.9x15.5%16.7%+13.5% −54.6%
PEN Penumbra, Inc. $12.6B78.4x11.4%8.9%+17.6% —
SNN Smith & Nephew plc $12.2B19.0x21.7%9.8%+11.5% —
ALGN Align Technology, Inc. $10.5B25.6x10.2%10.3%+4.4% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-09-22Officer/Director Change; Regulation FD; Exhibits
2026-08-18Officer/Director Change; Exhibits
2026-07-29Regulation FD; Exhibits
2026-07-29Earnings Release; Exhibits
2026-07-23Earnings Release; Officer/Director Change; Exhibits
2026-04-29Earnings Release; Exhibits

Context

Shares outstanding451,686,252
Free float99.7%
Institutional ownership87.7%
Beta0.82
Dividend yield0.20%
Last dividend$0.04 on 2026-10-23
50 / 200-day average$68.61 / $70.54
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where GEHC sits among 61 scored companies in Medical - Devices (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureGEHCIndustry medianIndustry percentileSector median
P/E (TTM) 19.7x 25.7x
26th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 3.23 1.33
93rd		 1.28
Price / sales 1.6x 3.3x
17th		 3.7x
Price / book 2.9x 3.5x
43rd		 3.6x
Price / tangible book —
Price / free cash flow 35.1x 26.8x
72nd		 21.2x
Price / operating cash flow 22.2x 19.5x
58th		 17.1x
Enterprise value $39.4B $2.0B
92nd		 $2.5B
EV / sales 1.9x 3.5x
18th		 3.8x
EV / EBITDA 11.3x 18.6x
32nd		 16.2x
EV / EBIT 16.0x 24.7x
21st		 23.0x
EV / free cash flow 44.0x 27.6x
72nd		 24.6x
Earnings yield 5.1% -0.7%
88th		 -0.3%
FCF yield 2.8% 1.9%
57th		 1.7%
Operating cash flow yield 4.5% 3.4%
58th		 2.9%
Graham number (per share) $43.67 $42.90
52nd		 $26.70

Profitability (TTM)

MeasureGEHCIndustry medianIndustry percentileSector median
Gross margin 42.9% 63.7%
13th		 65.1%
EBITDA margin 17.2% 9.3%
68th		 6.6%
Operating margin 12.7% 4.0%
72nd		 3.5%
EBIT margin 12.2% 1.4%
70th		 2.4%
Net margin 7.9% -1.7%
65th		 0.3%
NOPAT margin 9.9% 0.1%
68th		 2.7%
FCF margin 4.4% 3.0%
53rd		 4.3%
Operating cash flow margin 7.0% 8.5%
48th		 7.1%
R&D / revenue 6.5% 10.1%
32nd		 12.4%
SG&A / revenue 21.3% 46.6%
8th		 37.9%
Stock comp / revenue 0.6% 3.5%
10th		 4.5%
Effective tax rate 21.8% 21.0%
78th		 21.0%

Returns on capital

MeasureGEHCIndustry medianIndustry percentileSector median
ROE (on average equity) 15.4% -1.7%
81st		 0.8%
ROA 4.4% -1.1%
68th		 -0.3%
ROIC 10.6% 1.1%
69th		 5.5%
ROCE 8.5% 1.6%
68th		 2.3%
Return on tangible assets 6.8% 1.0%
67th		 1.7%
Cash ROIC (OCF / invested capital) 7.5% 7.0%
54th		 9.7%
Gross profitability (GP / assets) 23.3% 36.4%
18th		 29.9%
ROIC, 3-yr average 9.3% -1.0%
76th		 2.6%
ROIC, 5-yr average —
ROE, 5-yr average —
Incremental ROIC 50.4% 19.9%
63rd		 17.2%

Growth

MeasureGEHCIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 1.4% 11.5%
12th		 10.5%
Revenue growth (QoQ) 3.2% 7.8%
22nd		 7.2%
Revenue CAGR, 3 yr 11.9% 11.6%
53rd		 10.7%
Revenue CAGR, 5 yr —
Gross profit CAGR, 3 yr 14.6% 12.8%
62nd		 10.6%
Operating income CAGR, 3 yr 10.5% 12.0%
44th		 11.7%
Net income growth (TTM YoY) -29.0% 8.7%
33rd		 17.5%
Net income CAGR, 3 yr 5.8% 13.1%
35th		 11.3%
EPS growth (TTM YoY) -28.3% 7.8%
33rd		 19.2%
EPS CAGR, 3 yr 6.1% 14.5%
30th		 14.0%
EPS CAGR, 5 yr —
FCF growth (TTM YoY) -42.8% 16.8%
3rd		 18.6%
FCF CAGR, 3 yr -8.1% 32.2%
12th		 15.4%
Operating cash flow CAGR, 3 yr -0.6% 18.3%
16th		 11.9%
Book value CAGR, 3 yr 16.0% 5.2%
78th		 2.1%
Dividend CAGR, 3 yr 3.0% 2.5%
62nd		 2.2%
Sustainable growth rate 14.8% 10.9%
70th		 12.2%

Margin history & stability

MeasureGEHCIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 41.8% 64.5%
13th		 62.6%
Operating margin, 3-yr average 13.0% 4.3%
74th		 1.0%
Net margin, 3-yr average 9.1% -5.8%
72nd		 -2.6%
FCF margin, 3-yr average 6.8% 2.8%
57th		 3.2%
Revenue stability (0-1) 0.70 0.90
19th		 0.80
Earnings stability (0-1) 0.22 0.30
40th		 0.37
Margin stability (0-1) 0.97 0.96
72nd		 0.93

Liquidity (latest quarter)

MeasureGEHCIndustry medianIndustry percentileSector median
Cash & short-term investments $2.1B $184.9M
93rd		 $330.9M
Net cash (− = net debt) −$8.0B −$37.3M
7th		 $8.4M
Working capital $167.0M $318.0M
27th		 $381.1M
Current ratio 1.02 3.35
3rd		 3.02
Quick ratio 0.72 2.33
5th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.25 0.87
20th		 1.43
Defensive interval (days) 357 days 324 days
58th		 415 days

Leverage & solvency (latest quarter)

MeasureGEHCIndustry medianIndustry percentileSector median
Total debt $10.1B $263.7M
93rd		 $289.1M
Debt / equity 0.92 0.54
79th		 0.45
Net debt / equity 0.73 0.28
75th		 −0.13
Debt / assets 27.1% 27.9%
48th		 24.4%
Debt / capital 47.9% 35.1%
79th		 31.1%
Debt / EBITDA 2.90 2.56
55th		 2.62
Net debt / EBITDA 2.30 2.08
55th		 1.42
Interest coverage (EBIT / interest) 5.7x 0.4x
73rd		 2.1x
Cash interest coverage 3.2x 3.2x
50th		 3.6x
Debt payback (years of OCF) 7.1 yrs 3.4 yrs
70th		 2.7 yrs
Liabilities / assets 70.5% 49.8%
85th		 49.8%
IS credit model rating BB+ — —
Implied credit spread (bps) 400 225
63rd		 225

Efficiency

MeasureGEHCIndustry medianIndustry percentileSector median
Asset turnover 0.56 0.60
38th		 0.56
Fixed asset turnover 6.43 4.84
67th		 4.87
Inventory turnover 4.9 1.8
86th		 2.7
Receivables turnover 5.0 6.4
22nd		 6.4
Days sales outstanding 73 days 57 days
78th		 57 days
Days inventory outstanding 75 days 207 days
14th		 136 days
Days payables outstanding 98 days 59 days
83rd		 59 days
Cash conversion cycle (days) 50 days 214 days
10th		 70 days
Capex / revenue 2.6% 3.6%
33rd		 2.6%
Capex / depreciation 0.52 0.67
36th		 0.55
Operating expense ratio 27.2% 57.4%
7th		 56.5%

Cash flow & earnings quality

MeasureGEHCIndustry medianIndustry percentileSector median
Operating cash flow / net income 0.89 1.65
4th		 1.61
FCF / net income 0.56 1.30
7th		 1.36
FCF / operating cash flow 63.2% 63.6%
48th		 81.2%
Capex / operating cash flow 36.8% 36.4%
52nd		 18.8%
Accruals ratio 0.5% -5.2%
92nd		 -5.4%
Sloan accruals ratio -5.5% -1.3%
33rd		 -1.3%
Earnings quality score (0-1) 0.75 1.00
4th		 0.75

Dividends & buybacks

MeasureGEHCIndustry medianIndustry percentileSector median
Dividend yield 0.2% 0.0%
87th		 0.0%
Dividend per share (TTM) $0.14 $0.00
87th		 $0.00
Payout ratio (dividends / net income) 4.0% 0.0%
67th		 0.0%
Dividends / FCF 7.2% 0.0%
69th		 0.0%
Dividend growth (YoY) 9.4% 4.0%
78th		 4.5%
Buyback yield 1.3% 0.0%
77th		 0.0%
Shareholder yield (dividends + buybacks) 1.5% 0.0%
73rd		 0.0%
Share count change (YoY) -0.9% 1.4%
25th		 2.0%
Buybacks, last 5 years $800.0M $0
77th		 $0

Scores & forensic checks

MeasureGEHCIndustry medianIndustry percentileSector median
IS score 26 41
12th		 46
IS profitability 46 20
65th		 22
IS growth 23 60
7th		 60
IS value 57 39
83rd		 39
IS momentum 44 67
5th		 67
IS risk (safety) 30 65
23rd		 80
IS quality 61 49
58th		 49
IS balance sheet 48 50
43rd		 55
IS earnings quality 70 56
68th		 56
IS cash flow 29 32
20th		 41
Piotroski F-score (0-9) 5 6
35th		 5
Altman Z-score 1.7 3.0
28th		 3.2
Beneish M-score −2.53 −2.67
66th		 −2.62
Ohlson O-score −7.02 −7.26
52nd		 −7.16
IS credit score 49 62
35th		 62

Per share

MeasureGEHCIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $3.51 −$0.07
78th		 −$0.03
Book value per share $24.17 $10.13
77th		 $7.10
Tangible book per share −$13.24 $2.24
0th		 $1.91
Revenue per share $44.59 $12.68
88th		 $9.38
FCF per share $1.97 $0.62
67th		 $0.46
Operating cash flow per share $3.12 $1.25
65th		 $0.93
Cash per share $4.64 $2.47
72nd		 $3.51

Size (TTM)

MeasureGEHCIndustry medianIndustry percentileSector median
Market cap $31.4B $1.6B
90th		 $2.4B
Revenue $20.2B $815.1M
93rd		 $770.2M
EBITDA $3.5B $83.1M
93rd		 $56.1M
Net income $1.6B −$7.2M
93rd		 −$3.3M
Free cash flow $895.0M $38.8M
87th		 $41.2M
Total assets $37.2B $1.1B
93rd		 $1.3B
Shareholders' equity $11.0B $496.6M
92nd		 $568.4M
Employees 54,000 1,800
93rd		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-14Grogan William K
Chief Financial Officer
 Award / grant 62,256——62,256
2026-09-14Grogan William K
Chief Financial Officer
 Award / grant 12,840——75,096
2026-09-14Grogan William K
Chief Financial Officer
 Award / grant 31,877$64.25$2.0M31,877
2026-09-03Rackliffe Philip
CEO, AIS
 Tax withholding 798$70.56$56,30741,533
2026-09-03O'Neill Kevin Michael
CEO, PDx
 Tax withholding 718$70.56$50,66232,026
2026-09-03Newcomb George A.
Chief Accounting Officer
 Tax withholding 112$70.56$7,90310,515
2026-09-03Kass-Hout Taha
Chief Technology Officer
 Tax withholding 1,502$70.56$105,98188,467
2026-09-03Jimenez Frank R
GC & Corporate Secretary
 Tax withholding 1,480$70.56$104,42989,321
2026-09-03Holton Adam Y
Chief People Officer
 Tax withholding 673$70.56$47,48719,533
2026-09-03Estrampes Catherine
Chief Commer. & Growth Officer
 Tax withholding 508$70.56$35,84423,573
2026-09-03Arduini Peter J
Director, President and CEO
 Tax withholding 6,303$70.56$444,740241,606
2026-09-01Rackliffe Philip
CEO, AIS
 Tax withholding 290$71.23$20,65742,897

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayAugSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired14157,661$2.0M
Open-market buyAcquired8103,652$6.4M
Tax withholdingDisposed2139,154$2.7M
—Disposed1066,046$5.5M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 2 notices · 9,170 shares · $715,038
FiledFilerShares proposedEst. proceeds
2025-11-24Kenneth Stacherski4,585$353,045
2025-10-27Kenneth Stacherski4,585$361,993
2025-09-22Kenneth Stacherski19,524$1.5M
2025-09-12Kenneth Stacherski11,757$905,590
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 15 trades (7 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-11Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-07-30Ro KhannaHousePurchase$1,001 - $15,0002026-08-12
2026-07-07Ro KhannaHousePurchase$1,001 - $15,0002026-08-12
2026-07-06Ro KhannaHousePurchase$1,001 - $15,0002026-08-12
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
DODGE & COX37,864,164$2.4B8.38%
BlackRock, Inc.37,467,843$2.4B8.30%
VANGUARD CAPITAL MANAGEMENT LLC29,724,359$1.9B6.58%
STATE STREET CORP20,861,566$1.3B4.62%
VANGUARD PORTFOLIO MANAGEMENT LLC20,275,526$1.3B4.49%
Invesco Ltd.18,296,350$1.2B4.05%
BARROW HANLEY MEWHINNEY & STRAUSS LLC13,455,814$861.3M2.98%
GEODE CAPITAL MANAGEMENT, LLC12,871,800$820.8M2.85%
JPMORGAN CHASE & CO9,969,191$648.5M2.21%
NORGES BANK5,823,524$372.8M1.29%
DIMENSIONAL FUND ADVISORS LP5,401,410$345.8M1.20%
Boston Partners5,118,279$327.6M1.13%
MORGAN STANLEY4,972,209$318.3M1.10%
VAN ECK ASSOCIATES CORP4,482,631$286.9M0.99%
GOLDMAN SACHS GROUP INC4,446,565$284.6M0.98%

Institutional ownership by quarter

2023-092026-0687.7%
% of shares held by 13F filers
2023-092026-061,230
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-301,23087.7%142398471163
2026-03-311,26786.2%129389481159
2025-12-311,32690.0%18142646992
2025-09-301,26983.5%119481403134
2025-06-301,30384.2%123490457159
2025-03-311,35784.4%16150145198
2024-12-311,31785.6%222497391131
2024-09-301,25783.8%15746640686
2024-06-301,20282.3%100504373131
2024-03-311,24781.8%17044740680
2023-12-311,17282.1%16939441670
2023-09-301,08981.3%119403364123

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-08-07SCHEDULE 13G/ADodge & Cox8.3%37,864,164
2026-08-07SCHEDULE 13G/ADodge & Cox10.5%47,334,058
2026-05-14SCHEDULE 13G/ACapital Research Global Investors4.6%21,114,633
2026-04-29SCHEDULE 13GVanguard Capital Management7.3%33,370,111
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.04%$937.3M
VTSAX0.04%$937.3M
VTI0.04%$937.3M
VSMPX0.04%$937.3M
VFINX0.04%$775.5M
VFFSX0.04%$775.5M

Share structure

Shares outstanding451,686,252
Float450,236,789
Free float99.7%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$17.6B$18.3B$19.6B$19.7B$20.6B
Cost of revenue$10.4B$11.2B$11.6B$11.5B$12.4B
Gross profit$7.2B$7.2B$7.9B$8.2B$8.2B
R&D$816.0M$1.0B$1.2B$1.3B$1.3B
SG&A$3.6B$3.6B$4.3B$4.3B$4.2B
Operating income$2.8B$2.5B$2.4B$2.6B$2.8B
EBITDA$3.5B$3.2B$3.5B$3.7B$3.8B
Pretax income$2.9B$2.5B$2.4B$2.6B$2.8B
Income tax$600.0M$563.0M$743.0M$531.0M$614.0M
Net income$2.2B$1.9B$1.6B$2.0B$2.1B
EPS, diluted$4.90$4.22$3.02$4.34$4.55
Diluted shares454.7M453.9M458.0M459.0M460.3M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$556.0M$1.4B$2.5B$2.9B$4.5B
Receivables$3.8B$4.0B$4.3B$4.4B$4.0B
Inventory$1.9B$2.2B$2.0B$1.9B$2.2B
Total current assets$6.5B$7.8B$9.0B$9.5B$10.7B
PP&E, net$2.2B$2.3B$2.5B$2.5B$3.1B
Goodwill & intangibles$14.7B$14.3B$14.2B$14.2B$14.6B
Total assets$26.3B$27.5B$32.5B$33.1B$36.9B
Accounts payable$2.7B$3.1B$2.9B$3.0B$3.2B
Total current liabilities$6.8B$7.2B$9.0B$9.6B$9.1B
Long-term debt$31.0M$8.2B$8.4B$7.4B$9.5B
Total liabilities$9.4B$17.9B$25.1B$24.4B$26.3B
Shareholders' equity$16.9B$9.6B$7.3B$8.7B$10.6B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$2.3B$1.9B$1.6B$2.0B$2.2B
Depreciation & amortization$625.0M$633.0M$610.0M$580.0M$578.0M
Stock-based compensation$76.0M$67.0M$114.0M$125.0M$130.0M
Change in working capital−$1.4B−$293.0M$22.0M−$59.0M−$357.0M
Operating cash flow$1.6B$2.1B$2.1B$2.0B$2.0B
Capital expenditure−$248.0M−$310.0M−$387.0M−$401.0M−$482.0M
Free cash flow$1.4B$1.8B$1.7B$1.6B$1.5B
Investing cash flow−$1.8B−$398.0M−$558.0M−$914.0M−$1.0B
Net debt issued / repaid−$12.0M$8.2B$1.1B−$423.0M$967.0M
Buybacks$0$0$0$0−$200.0M
Dividends paid$0$0−$41.0M−$55.0M−$64.0M

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2022FY2023FY2024FY2025
Gross margin39.1%40.5%41.7%43.5%
Operating margin15.7%12.5%13.3%13.3%
Net margin11.2%8.0%10.1%8.6%
FCF margin19.5%8.8%7.9%7.7%
ROE5.9%19.0%25.6%17.8%
ROIC3.7%11.5%14.0%13.0%
ROA2.0%5.2%6.1%4.8%
Debt / equity0.921.381.110.96
Interest coverage13.0x5.4x6.1x5.8x
Current ratio1.091.001.001.18
Revenue growth—+295.9%+0.6%−0.4%
EPS growth—+180.5%+26.8%−15.9%
P/E at year end47.6x22.5x18.0x22.5x
EV / EBITDA at year end35.8x12.1x11.5x12.1x
FCF yield at year end3.66%4.86%4.33%3.99%
Dividend payout0.0%2.6%2.8%3.8%

Revenue by segment

FY2023FY2024FY2025
Imaging Segment$10.6B$8.9B$9.2B
Ultrasound Segment$3.5B——
PCS Segment$3.1B$3.1B$3.1B
PDx Segment$2.3B$2.5B$2.9B

Revenue by region · FY2025

Other Countries$9.4B · 46%
UNITED STATES$9.2B · 44%
CHINA$2.0B · 10%

Street estimates by fiscal year

Next report 2026-10-28 · consensus EPS $1.21 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$21.7B$21.6B – $21.8B$4.92$4.89 – $4.991314.1x
2027$22.7B$22.5B – $22.9B$5.43$5.15 – $5.581312.8x
2028$23.8B$23.3B – $24.4B$6.04$5.40 – $6.40911.5x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-07-29$1.04$1.13+8.7%$5.3B$5.3B+0.6%
2026-04-29$1.04$0.99−4.8%$5.0B$5.1B+1.8%
2026-02-04$1.40$1.44+2.9%$5.6B$5.7B+1.5%
2025-10-29$1.05$1.07+1.9%$5.1B$5.1B+1.1%
2025-07-30$0.92$1.06+15.5%$5.0B$5.0B+0.7%
2025-04-30$0.91$1.01+10.5%$4.7B$4.8B+2.5%
2025-02-13$1.26$1.45+15.1%$5.3B$5.3B−0.2%
2024-10-30$1.05$1.14+8.6%$4.9B$4.9B−0.1%
2024-07-31$0.98$1.00+2.0%$4.9B$4.8B−0.8%
2024-04-30$0.91$0.90−1.1%$4.8B$4.7B−3.2%
2024-02-06$1.07$1.18+10.3%$5.1B$5.2B+2.2%
2023-10-31$0.90$0.99+10.0%$4.8B$4.8B+0.4%
2023-07-25$0.87$0.92+5.7%$4.8B$4.8B+0.5%
2023-04-25$0.79$0.85+7.6%$4.6B$4.7B+1.6%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.306-150.406-220.206-290.307-060.607-130.407-200.807-270.408-030.208-100.208-170.208-240.308-31
Week ofNotionalSharesTrades
2026-08-31$251.4M3,584,56077,923
2026-08-24$203.1M2,772,30568,952
2026-08-17$236.9M3,204,86877,608
2026-08-10$228.4M3,130,46574,963
2026-08-03$350.1M4,992,08494,679
2026-07-27$800.1M11,826,064169,903

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1556.3%
DateShort shareShort volumeTotal volume
2026-10-1556.3%627,6761,114,211
2026-10-1470.6%1,328,2941,880,899
2026-10-1372.5%923,6761,273,457
2026-10-1263.9%901,5521,411,278
2026-10-0959.9%648,5781,082,460
2026-10-0868.1%794,3451,166,729
2026-10-0752.3%516,214987,845
2026-10-0650.4%439,406871,699
2026-10-0561.9%568,551918,193
2026-10-0252.9%498,879943,002
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+7.1Jan+9.1Feb-2.8Mar-9.0Apr+0.8May+2.8Jun+0.6Jul-0.7Aug+4.6Sep-2.4Oct+1.1Nov+1.6Dec
MonthAvg returnUp yearsYears
Jan+7.1%50%4
Feb+9.1%75%4
Mar−2.8%25%4
Apr−9.0%0%3
May+0.8%33%3
Jun+2.8%100%3
Jul+0.6%33%3
Aug−0.7%67%3
Sep+4.6%67%3
Oct−2.4%0%3
Nov+1.1%67%3
Dec+1.6%50%4
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1461.0
MFI52.7
ADX21.6
Stochastic %K / %D84.4 / 86.7
Williams %R-21.6
CCI184
TSI / signal7.2 / -8.1
Chaikin money flow0.11
ATR$1.73
Bollinger width10.7%
Volume vs 20-day avg0.82x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$66.36 (+4.8%)
SMA 50$68.59 (+1.4%)
SMA 200$70.47 (−1.3%)
EMA 21$67.02 (+3.8%)
EMA 50$67.18 (+3.6%)
EMA 200$69.56 (+0.0%)
Bollinger upper$69.90 (−0.5%)
Bollinger lower$62.81 (+10.8%)
Parabolic SAR$64.57 (+7.7%)
Open the live chart, 110+ indicators

About GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.

https://www.gehealthcare.com

Key executives

NameTitlePayBorn
Peter J. ArduiniPresident, Chief Executive Officer & Director$3.7M1965
Frank R. JimenezGeneral Counsel & Corporate Secretary$1.9M1965
Taha Kass-HoutChief Science & Technology Officer$1.9M1972
Adam HoltonChief People Officer$1.8M1971
William K. GroganChief Financial Officer$1.3M1979
Jeannette BankesPresident & Chief Executive Officer of Patient Care Solutions$1.1M1971
George Andrew NewcombController & Chief Accounting Officer—1967
Kevin Michael O'NeillPresident & Chief Executive Officer of Pharmaceutical Diagnostics—1969

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
None on file.

Employees

50k202251k202353k202454k2025

Dividends

Ex-dateAmountPaid
2026-10-23$0.042026-11-13
2026-07-24$0.0352026-08-14
2026-04-02$0.0352026-05-15
2026-01-09$0.0352026-02-13
2025-10-24$0.0352025-11-14
2025-07-25$0.0352025-08-15
2025-04-25$0.0352025-05-15
2025-01-14$0.0352025-02-14

Moat model

Weak · Cost Advantage · 2026-06-30
Cost advantage75
Intangibles42
Switching costs32
Network effect45
Efficient scale55
Our component scores (0-100) and overall 48.5; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms